MCID: ADR005
MIFTS: 60

Adrenal Carcinoma

Categories: Cancer diseases, Endocrine diseases, Nephrological diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Adrenal Carcinoma

MalaCards integrated aliases for Adrenal Carcinoma:

Name: Adrenal Carcinoma 11 14
Adrenal Cancer 11 19 75 53 71 33
Adrenal Gland Cancer 11 41 14 33
Malignant Neoplasm of Adrenal Gland 11 31
Adrenal Gland Neoplasms 43 71
Malignant Neoplasm of Adrenal Gland, Unspecified 33
Primary Malignant Neoplasm of Adrenal Gland 33
Malignant Neoplasm of Suprarenal Gland 33
Malignant Tumour of Adrenal Gland 33
Carcinoma of the Adrenal Gland 11
Tumor of the Adrenal Gland 11
Neoplasm of Adrenal Gland 11
Adrenocortical Carcinoma 71
Adrenal Gland Malignancy 33
Malignant Adrenal Tumor 11
Suprarenal Gland Cancer 33
Adrenal Gland Neoplasm 16
Suprarenal Cancer 33
Adrenal Neoplasm 11

Classifications:



External Ids:

Disease Ontology 11 DOID:3950 DOID:3953
ICD9CM 34 194.0
MeSH 43 D000310
NCIt 49 C2859 C9338
SNOMED-CT 68 127021009 93665005
ICD10 31 C74 C74.9
UMLS 71 C0001624 C0206686 C0750887

Summaries for Adrenal Carcinoma

MedlinePlus: 41 Your adrenal, or suprarenal, glands are located on the top of each kidney. These glands produce hormones that you can't live without, including sex hormones and cortisol, which helps you respond to stress and has many other functions. A number of disorders can affect the adrenal glands, including tumors. Tumors can be either benign or malignant. Benign tumors aren't cancer. Malignant ones are. Most adrenal gland tumors are benign. They usually do not cause symptoms and may not require treatment. Malignant adrenal gland cancers are uncommon. Types of tumors include: Adrenocortical carcinoma - cancer in the outer part of the gland Neuroblastoma, a type of childhood cancer Pheochromocytoma - a rare tumor that is usually benign Symptoms depend on the type of cancer you have. Treatments may include surgery, chemotherapy, or radiation therapy.

MalaCards based summary: Adrenal Carcinoma, also known as adrenal cancer, is related to adrenal medulla cancer and adrenal neuroblastoma, and has symptoms including fever and flank pain. An important gene associated with Adrenal Carcinoma is IGF2 (Insulin Like Growth Factor 2), and among its related pathways/superpathways are Diseases of glycosylation and Oxidation by cytochrome P450. The drugs Etomidate and Iodine have been mentioned in the context of this disorder. Affiliated tissues include cortex, adrenal glands which are located above the kidneys and adrenal gland, and related phenotypes are Reduced mammosphere formation and Increased proliferation

GARD: 19 Adrenal cancer is a rare form of cancer that occurs due to abnormal and uncontrolled cell growth in the adrenal glands (small glands that sit above each kidney). In most cases, the underlying cause of the condition is unknown. However, certain genetic conditions such as multiple endocrine neoplasia type 2, Li-Fraumeni syndrome, Von Hippel-Lindau syndrome, neurofibromatosis type I, and Carney complex are associated with an increased risk of developing adrenal tumors and cancer.

Disease Ontology 11 Adrenal carcinoma: An adrenal cancer that is located in the cortex (steroid hormone-producing tissue) of the adrenal gland and that has material basis in abnormally proliferating cells derives from epithelial cells.

Adrenal gland cancer: An endocrine gland cancer located in the adrenal glands which are located above the kidneys.

Wikipedia: 75 An adrenal tumor or adrenal mass is any benign or malignant neoplasms of the adrenal gland, several of... more...

Related Diseases for Adrenal Carcinoma

Diseases related to Adrenal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 384)
# Related Disease Score Top Affiliating Genes
1 adrenal medulla cancer 32.4 SYP MIR483 CHGA
2 adrenal neuroblastoma 32.3 SYP CHGA
3 mixed cell type cancer 31.3 TP53 SYP CHGA
4 adrenal gland disease 31.2 TP53 SYP REN PRKAR1A POMC NR5A1
5 small cell carcinoma 31.0 TP53 SYP CHGA
6 neuroendocrine carcinoma 30.9 SYP MEN1 CHGA
7 ewing sarcoma 30.8 TP53 SYP IGF2 CHGA
8 premature ovarian failure 7 30.7 POMC NR5A1
9 hypokalemia 30.7 REN POMC KCNJ5 CYP17A1 CYP11B2 CYP11B1
10 leiomyoma 30.7 TP53 IGF2 CYP17A1
11 amenorrhea 30.6 POMC NR5A1 CYP17A1
12 large cell neuroendocrine carcinoma 30.6 TP53 SYP MEN1 CHGA
13 neurilemmoma 30.6 SYP PRKAR1A MLANA
14 adrenogenital syndrome 30.6 SYP CYP21A2
15 islet cell tumor 30.5 SYP POMC MIR483 MEN1 IGF2 CHGA
16 pheochromocytoma 30.5 SYP REN POMC MEN1 IGF2 CHGA
17 multiple endocrine neoplasia 30.5 SYP PRKAR1A POMC MEN1 CHGA
18 hypoglycemia 30.4 POMC KCNJ5 IGF2 CHGA
19 neuroendocrine tumor 30.4 SYP POMC MEN1 CHGA
20 conn's syndrome 30.3 TP53 SYP REN PRKAR1A POMC NR5A1
21 adrenal cortical carcinoma 30.3 ZNRF3 TP53 SYP REN PRKAR1A POMC
22 leiomyosarcoma 30.3 TP53 MLANA IGF2
23 hypoaldosteronism 30.3 REN POMC CYP11B2
24 adenoma 30.3 TP53 SYP REN PRKAR1A POMC MEN1
25 vascular cancer 30.2 TP53 SYP MLANA
26 malignant pheochromocytoma 30.2 SYP MIR483 CHGA
27 hypoadrenocorticism, familial 30.2 REN POMC NR5A1 HSD3B2 CYP21A2 CYP17A1
28 extra-adrenal pheochromocytoma 30.2 SYP CHGA
29 lipoid congenital adrenal hyperplasia 30.2 REN POMC NR5A1 HSD3B2 CYP21A2 CYP17A1
30 lung benign neoplasm 30.2 TP53 SYP CHGA
31 mccune-albright syndrome 30.2 PRKAR1A POMC MEN1 ARMC5
32 multiple endocrine neoplasia, type i 30.2 SYP PRKAR1A POMC MIR483 MEN1 CHGA
33 adrenal adenoma 30.1 REN PRKAR1A POMC MIR483 MEN1 KCNJ5
34 small cell cancer of the lung 30.1 TP53 SYP POMC CHGA
35 pituitary adenoma 30.1 PRKAR1A POMC MEN1 CHGA
36 acne 30.1 POMC CYP21A2 CYP17A1
37 primary hyperparathyroidism 30.1 PRKAR1A MEN1 CHGA
38 hyperparathyroidism 30.1 PRKAR1A MEN1 CHGA
39 hypogonadotropic hypogonadism 30.1 POMC NR5A1 HSD3B2 CYP21A2 CYP17A1
40 premature menopause 30.0 TP53 REN POMC NR5A1 CYP21A2 CYP17A1
41 hyperinsulinemic hypoglycemia 30.0 SYP POMC MEN1 KCNJ5 IGF2 CHGA
42 li-fraumeni syndrome 30.0 ZNRF3 TP53 PRKAR1A MIR483 MEN1 IGF2
43 beckwith-wiedemann syndrome 29.9 ZNRF3 TP53 PRKAR1A MIR483 MEN1 IGF2
44 adrenal cortical adenoma 29.9 SYP REN PRKAR1A POMC NR5A1 MLANA
45 adenomatoid tumor 10.7
46 adrenocortical carcinoma, hereditary 10.5
47 basophilic adenocarcinoma 10.5 POMC GRN
48 acute adrenal insufficiency 10.5 POMC CYP21A2
49 ureter leiomyoma 10.5 MLANA MEN1
50 basophil adenoma 10.5 PRKAR1A POMC

Graphical network of the top 20 diseases related to Adrenal Carcinoma:



Diseases related to Adrenal Carcinoma

Symptoms & Phenotypes for Adrenal Carcinoma

UMLS symptoms related to Adrenal Carcinoma:


fever; flank pain

GenomeRNAi Phenotypes related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 CHGA CYP11B1 CYP21A2 HSD3B2 IGF2 KCNJ5
2 Increased proliferation GR00094-A 8.96 MEN1 TP53

MGI Mouse Phenotypes related to Adrenal Carcinoma:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.26 CHGA CYP11B1 CYP11B2 GRN IGF2 MEN1
2 growth/size/body region MP:0005378 10.21 ARMC5 CHGA CYP11B1 CYP11B2 CYP17A1 CYP21A2
3 renal/urinary system MP:0005367 10.11 CHGA CYP11B1 CYP11B2 GRN IGF2 POMC
4 endocrine/exocrine gland MP:0005379 10.06 ARMC5 CHGA CYP11B1 CYP11B2 IGF2 MEN1
5 muscle MP:0005369 10.03 CHGA CYP11B1 CYP11B2 IGF2 MEN1 PRKAR1A
6 cardiovascular system MP:0005385 10.03 CHGA CYP11B1 CYP11B2 CYP17A1 IGF2 KCNJ5
7 liver/biliary system MP:0005370 10.01 CYP11B1 CYP11B2 GRN IGF2 MEN1 POMC
8 behavior/neurological MP:0005386 9.97 CYP11B1 CYP11B2 CYP17A1 CYP21A2 GRN IGF2
9 pigmentation MP:0001186 9.89 GRN MLANA POMC PRKAR1A TP53
10 reproductive system MP:0005389 9.7 CHGA CYP11B1 CYP11B2 CYP17A1 GRN IGF2
11 mortality/aging MP:0010768 9.5 ARMC5 CHGA CYP11B1 CYP11B2 CYP17A1 CYP21A2

Drugs & Therapeutics for Adrenal Carcinoma

Drugs for Adrenal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etomidate Approved Phase 3 33125-97-2 667484
2
Iodine Approved, Investigational Phase 3 7553-56-2 807
3
Streptozocin Approved, Investigational Phase 3 18883-66-4, 66395-18-4 29327
4
Picropodophyllin Approved, Investigational Phase 3 518-28-5, 477-47-4 10607 72435
5
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
6
Etoposide Approved Phase 3 33419-42-0 36462
7
Lenograstim Approved, Investigational Phase 3 135968-09-1
8
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
9
Cadexomer iodine Experimental Phase 3 94820-09-4
10 Anesthetics, Intravenous Phase 3
11 Anesthetics, General Phase 3
12 Anesthetics Phase 3
13 Hypnotics and Sedatives Phase 3
14 Antimitotic Agents Phase 3
15 Keratolytic Agents Phase 3
16 Tubulin Modulators Phase 3
17 Dermatologic Agents Phase 3
18 Anti-Bacterial Agents Phase 3
19
Etoposide phosphate Phase 3 16760419
20 Antibiotics, Antitubercular Phase 3
21 Liposomal doxorubicin Phase 3
22
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
23
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
24
Acetic acid Approved Phase 2 64-19-7 176
25
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
26
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
27
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
28
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
29
Lactitol Approved, Investigational Phase 2 585-86-4 157355
30
Sodium citrate Approved, Investigational Phase 2 68-04-2 23431961
31
Tamoxifen Approved Phase 2 10540-29-1, 54965-24-1 2733526
32
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 11947679 6857599
33
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
34
Ipilimumab Approved Phase 2 477202-00-9
35
Mitotane Approved Phase 2 53-19-0 4211
36
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
37
Ketoconazole Approved, Investigational Phase 2 65277-42-1, 142128-57-2 47576 3823 638701
38
Metyrapone Approved, Investigational Phase 2 54-36-4 4174
39
Lenvatinib Approved, Investigational Phase 2 417716-92-8 9823820
40
Hydrocortisone succinate Approved Phase 2 2203-97-6 3643
41
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
42
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 3640 5754
43
Nivolumab Approved Phase 2 946414-94-4
44
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 22737-96-8, 68-26-8 5280382 445354
45
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
46
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
47
(-)-Gossypol Investigational Phase 2 303-45-7, 90141-22-3 3503
48
Zuretinol acetate Investigational Phase 2 127-47-9, 29584-22-3 10245972
49
Rivoceranib Investigational Phase 2 811803-05-1 11315474
50
Suramin Investigational Phase 2 129-46-4, 145-63-1 5361

Interventional clinical trials:

(show top 50) (show all 117)
# Name Status NCT ID Phase Drugs
1 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Transperitoneal Laparoscopic Adrenalectomy With a Five-year Follow-up Completed NCT01959711 Phase 4
2 Combined 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) and 123I-Iodometomidate (123I-IMTO) Imaging for Adrenal Neoplasia Unknown status NCT02010957 Phase 3
3 Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence Unknown status NCT00777244 Phase 3 MITOTANE
4 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence Unknown status NCT03723941 Phase 3 Cisplatin plus Etoposide
5 Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening Completed NCT00037843 Phase 3 I-131 Iodocholesterol
6 Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation Completed NCT00997594 Phase 2, Phase 3
7 First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment Completed NCT00094497 Phase 3 Etoposide;Doxorubicin;Cisplatin;Streptozotocin;Mitotane
8 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Completed NCT00924989 Phase 3 OSI-906
9 A Randomized Registry Trial of Adjuvant Mitotane vs. Mitotane With Cisplatin/Etoposide After Primary Surgical Resection of Localized Adrenocortical Carcinoma With High Risk of Recurrence (ADIUVO-2 Trial) Recruiting NCT03583710 Phase 3 Cisplatin;Etoposide;Mitotane
10 Treatment of Adrenocortical Tumors With Surgery Plus Lymph Node Dissection and Multiagent Chemotherapy: A Groupwide Phase III Study Active, not recruiting NCT00304070 Phase 3 doxorubicin hydrochloride;cisplatin;mitotane;etoposide
11 Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Unknown status NCT03145285 Phase 2 Abiraterone Acetate
12 Sorafenib Plus Paclitaxel Metronomic Chemotherapy in Adreno-Cortical-Carcinoma Patients Progressing After 1st or 2nd Line Cytotoxic Chemotherapy Unknown status NCT00786110 Phase 2 Sorafenib;Paclitaxel
13 Multicenter, Prospective, Non-randomized, Phase II Trial Designed to Evaluate the Activity of Cabazitaxel in Patients With Advanced Adreno-Cortical- Carcinoma Progressing After Previous Chemotherapy Lines Unknown status NCT03257891 Phase 2 Cabazitaxel
14 Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Completed NCT00454103 Phase 1, Phase 2 123I-Iodometomidate
15 A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease Completed NCT02468193 Phase 2 Osilodrostat
16 A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC) Completed NCT00848016 Phase 2 R-(-)-gossypol acetic acid
17 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Completed NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
18 Sunitinib in Refractory Adrenocortical-Carcinoma Patients Progressing After Cytotoxic Chemotherapy Completed NCT00453895 Phase 2 Sunitinib
19 A Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) Completed NCT00215202 Phase 2 Iressa (ZD1839)
20 Phase II Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma Completed NCT00324012 Phase 2 cisplatin, taxotere
21 A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection Completed NCT00001339 Phase 2 doxorubicin, vincristine, and etoposide with mitotane
22 Phase II Clinical Trial of Dovitinib (TKI-258) in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma Completed NCT01514526 Phase 2 Dovitinib
23 A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors Completed NCT00831844 Phase 2
24 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
25 A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors Completed NCT00091182 Phase 2 oxaliplatin
26 A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors Completed NCT01262235 Phase 1, Phase 2 TKM-080301
27 A Study of Combination Chemotherapy & Surgical Resection in the Tx of Adrenocortical Cancer: Mitotane & Continuous Infusion Doxorubicin, Vincristine & Etoposide w/the P-glycoprotein Antagonist, Tariquidar (XR9576), Before & After Surgical Resection Completed NCT00071058 Phase 2 XR9576 (Tariquidar)
28 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer Completed NCT01255137 Phase 2 Axitinib
29 SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor Recruiting NCT05436639 Phase 2 SPI-62 dose1;SPI-62 dose 2;SPI-62 dose 3;SPI-62 dose 4;Placebo
30 A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma Recruiting NCT04187404 Phase 1, Phase 2
31 A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Cabozantinib in Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma Recruiting NCT03612232 Phase 2 Cabozantinib-s-malate
32 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Recruiting NCT03127774 Phase 2 Cisplatin;Sodium thiosulfate
33 A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours Recruiting NCT03746431 Phase 1, Phase 2 [111In]-FPI-1547 Injection;[225Ac]-FPI-1434 Injection multi-dose;[225Ac]-FPI-1434 Injection single-dose
34 A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
35 A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors Recruiting NCT05012397 Phase 2 RAIN-32
36 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
37 Phase I/II Trial of Anti-CTLA4-NF mAb (BMS-986218) in Combination With Nivolumab and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid Malignancies Active, not recruiting NCT04785287 Phase 1, Phase 2
38 A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Active, not recruiting NCT02673333 Phase 2 Pembrolizumab
39 A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma Active, not recruiting NCT03370718 Phase 2 Cabozantinib
40 Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Active, not recruiting NCT02721732 Phase 2
41 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors Active, not recruiting NCT02867592 Phase 2 Cabozantinib;Cabozantinib S-malate
42 A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma Not yet recruiting NCT05634577 Phase 2 Mitotane;Pembrolizumab
43 A Multicentre, Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma. Not yet recruiting NCT05563467 Phase 2 Pembrolizumab 25 MG/ML [Keytruda]
44 Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma Not yet recruiting NCT04318730 Phase 2 Camrelizumab
45 A Prospective Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma After Failure of Platinum- and Mitotane-Based Chemotherapy Not yet recruiting NCT05036434 Phase 2 Pembrolizumab / Lenvatinib
46 Randomized Control Trial of Adrenalectomy Versus Observation for Subclinical Hypercortisolism Terminated NCT02001051 Phase 2
47 Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Adrenal Gland Terminated NCT00003453 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
48 Multi-Institutional Phase II Study of IMC-A12, a Recombinant Human IgG1 Monoclonal Antibody Directed at the Type I Insulin-Like Growth Factor Receptor IGF1R, in Adrenocortical Carcinoma: IMC-A12 With Mitotane vs Mitotane Alone Terminated NCT00778817 Phase 2 mitotane
49 Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma Terminated NCT02720484 Phase 2 Nivolumab
50 Evaluation of Suramin in Advanced Adrenal Cortical Carcinoma, Phase II Terminated NCT00002921 Phase 2 suramin;therapeutic hydrocortisone

Search NIH Clinical Center for Adrenal Carcinoma

Cochrane evidence based reviews: adrenal gland neoplasms

Genetic Tests for Adrenal Carcinoma

Anatomical Context for Adrenal Carcinoma

Organs/tissues related to Adrenal Carcinoma:

FMA: Cortex, Adrenal Glands Which Are Located Above The Kidneys
MalaCards : Adrenal Gland, Thyroid, Cortex, Kidney, Adrenal Cortex, Lymph Node, T Cells

Publications for Adrenal Carcinoma

Articles related to Adrenal Carcinoma:

(show top 50) (show all 1192)
# Title Authors PMID Year
1
Effects of epidural anesthesia in pheochromocytoma and paraganglioma surgeries: A protocol for systematic review and meta-analysis. 41
36451496 2022
2
Differential diagnostic value of plain CT scan in adrenal adenoma and non-adenoma: A two-center control study of mean attenuation value, minimum attenuation value, and CT histogram. 41
36440234 2022
3
The prevalence and spectrum of reported incidental adrenal abnormalities in abdominal computed tomography of cancer patients: The experience of a comprehensive cancer center. 41
36457558 2022
4
The modification and expression of 21-hydroxylase gene in normal human adrenal gland and adrenal cancer. 53 62
1687042 1991
5
Risk factors for venous thromboembolism (VTE) after adrenalectomy for adrenal cortical neoplasms. 62
35997946 2022
6
French AFU Cancer Committee Guidelines Update 2022-2024: Adrenal tumor -  Assessment of an adrenal incidetaloma and oncological management. 62
36400477 2022
7
Metabolomics-A Tool to Find Metabolism of Endocrine Cancer. 62
36422294 2022
8
Solitary Fibrous Tumor of the Adrenal Gland. 62
35993354 2022
9
Automated extraction of incidental adrenal nodules from electronic health records. 62
36207197 2022
10
Listeria monocytogenes bacteremia mimicking the systemic metastasis of adrenal cancer: a case report. 62
36243700 2022
11
Liquid biopsy for the assessment of adrenal cancer heterogeneity: where do we stand? 62
35552979 2022
12
[Diagnostic workup of adrenal masses]. 62
35789278 2022
13
[Are there still indications for open adrenalectomy?] 62
35788865 2022
14
Spectrum of Adrenal Lesions on Fine-Needle Aspiration Cytology: A Tertiary Care Centre Experience. 62
36119427 2022
15
Composite pheochromocytoma with spindle cell sarcoma - a rare tumor of the adrenal gland: case report. 62
35304732 2022
16
Eighth International Adrenal Cancer Symposium Brescia, Italy, September 30 to October 1-2, 2021. 62
35867326 2022
17
Metastatic primary ovarian carcinoma of the adrenal gland. 62
36041904 2022
18
N-type calcium channel v2.2 is a target of TCF21 in adrenocortical carcinomas. 62
35603952 2022
19
Malignant Peripheral Nerve Sheath Tumor of the Adrenal Gland: A De novo Case. 62
36185956 2022
20
[A Rare Case of Adrenal Metastasis Diagnosed before Discovery of Invasive Ductal Breast Cancer which was Confirmed to Be the Primary Site]. 62
35924707 2022
21
Massive adrenocortical carcinoma presenting as peripheral edema: a case report. 62
35725572 2022
22
An incidental finding behind adrenal incidentaloma. 62
35642689 2022
23
A novel in-frame GFAP p.E138_L148del mutation in Type II Alexander disease with atypical phenotypes. 62
35246666 2022
24
Adrenal carcinoma: a case report. 62
35637536 2022
25
Adrenal Surgery in the Era of Multidisciplinary Endocrine Tumor Boards. 62
35533674 2022
26
Adrenal and Mesenteric Teratomas in Infants: Common Tumors in Uncommon Sites. 62
35733597 2022
27
RNA-seq and Mitochondrial DNA Analysis of Adrenal Gland Metastatic Tissue in a Patient with Renal Cell Carcinoma. 62
35453788 2022
28
Biological response of adrenal carcinoma and melanoma cells to mitotane treatment. 62
35261634 2022
29
[Diagnostic value of ct in examination of patients with adrenal cancer]. 62
36104962 2022
30
A 15-Year Change of an Adrenal Endothelial Cyst. 62
35450977 2022
31
Clinical validation of a 90-gene expression test for tumor tissue of origin diagnosis: a large-scale multicenter study of 1417 patients. 62
35255924 2022
32
Lung Cancer Metastasis to the Pituitary Gland. 62
35371745 2022
33
[Adrenocortical Oncocytic Tumor : A Report of Two Cases]. 62
35259862 2022
34
Cancer risk in adrenalectomy: are adrenal lesions equal or more than 4 cm a contraindication for laparoscopy? 62
33650006 2022
35
Quantitation of Aldosterone in Serum or Plasma Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). 62
36127577 2022
36
Primary Adrenal Glomus Tumor: The First Case Report. 62
34644713 2022
37
Pheochromocytoma with fever and iron deficiency anemia. 62
36304617 2022
38
Adrenal carcinoma as the first manifestation of a Li‑Fraumeni syndrome in three paediatric patients. 62
35593669 2022
39
Modulation of Autophagy in Adrenal Tumors. 62
35966083 2022
40
Analysis of adrenalectomy for the treatment of adrenal diseases performed by the Public Health Service in São Paulo between 2008 and 2019. 62
35946638 2022
41
Adrenal Castleman's Disease: Case Report and Review of Literature. 62
35261526 2022
42
Mixed corticomedullary tumor of the adrenal gland. 62
36187098 2022
43
Integrated Analyses Reveal Potential Functional N6-Methyladenosine-Related Long Noncoding RNAs in Adrenocortical Adenocarcinoma. 62
35669515 2022
44
Metastatic bilateral adrenal sarcomatoid carcinoma: Evaluation by 18F-FDG PET/CT. 62
35800422 2022
45
Novel CYP11B-ligand [123/131I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience. 62
34215922 2021
46
Feminizing adrenocortical adenoma in a girl from a resource-limited setting: a case report. 62
34930443 2021
47
Accuracy of the dexamethasone suppression test for the prediction of autonomous cortisol secretion-related comorbidities in adrenal incidentalomas. 62
34273083 2021
48
Solitary Fibrous Tumor of Adrenal Gland and Review of the Literature. 62
35032374 2021
49
Transfer learning for fluence map prediction in adrenal stereotactic body radiation therapy. 62
34808605 2021
50
Cancers Detected During the Evaluation Before Bariatric Surgery in Obese Patients: a High-Risk Population for Cancers and Their Prevalence. 62
34674140 2021

Variations for Adrenal Carcinoma

Cosmic variations for Adrenal Carcinoma:

8 (show top 50) (show all 118)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88301868 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.389T>G p.V130G 3:10146562-10146562 31
2 COSM90654925 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.260T>C p.V87A 3:10142107-10142107 31
3 COSM88294143 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.260T>C p.V87A 3:10142107-10142107 31
4 COSM90652830 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.373G>T p.V125F 3:10149819-10149819 31
5 COSM88293303 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.475A>G p.K159E 3:10149798-10149798 31
6 COSM88288959 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.482G>A p.R161Q 3:10149805-10149805 31
7 COSM88296074 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.250G>C p.V84L 3:10142097-10142097 31
8 COSM88292246 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.227T>A p.F76Y 3:10142074-10142074 31
9 COSM90652721 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.368A>G p.Q123R 3:10149814-10149814 31
10 COSM88292324 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.496G>T p.V166F 3:10149819-10149819 31
11 COSM90657160 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.250G>C p.V84L 3:10142097-10142097 31
12 COSM88305342 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.492G>T p.Q164H 3:10149815-10149815 31
13 COSM90653943 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.352A>G p.K118E 3:10149798-10149798 31
14 COSM90668341 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.369G>T p.Q123H 3:10149815-10149815 31
15 COSM88292236 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.491A>G p.Q164R 3:10149814-10149814 31
16 COSM90652730 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.227T>A p.F76Y 3:10142074-10142074 31
17 COSM90648957 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.359G>A p.R120Q 3:10149805-10149805 31
18 COSM90664073 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.341-3225T>G p.? 3:10146562-10146562 31
19 COSM90811579 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.2753T>C p.M918T 10:43121968-43121968 31
20 COSM92347003 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.2753T>C p.M918T 10:43121968-43121968 31
21 COSM142343426 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.1289+3268T>C p.? 10:43114500-43114500 31
22 COSM142343204 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.*102T>C p.? 10:43121968-43121968 31
23 COSM92347226 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.1900T>C p.C634R 10:43114500-43114500 31
24 COSM90811811 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.1900T>C p.C634R 10:43114500-43114500 31
25 COSM93530486 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.226G>T p.E76* 17:31159031-31159031 31
26 COSM93656552 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1885G>A p.G629R 17:31225134-31225134 31
27 COSM93692982 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.5665G>T p.E1889* 17:31330351-31330351 31
28 COSM93650970 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1466A>G p.Y489C 17:31214524-31214524 31
29 COSM120509060 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1466A>G p.Y489C 17:31214524-31214524 31
30 COSM93535461 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.3158C>A p.S1053* 17:31230886-31230886 31
31 COSM109968573 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.226G>T p.E76* 17:31159031-31159031 31
32 COSM109960979 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1466A>G p.Y489C 17:31214524-31214524 31
33 COSM93512112 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1885G>A p.G629R 17:31225134-31225134 31
34 COSM93508888 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.205-1G>C p.? 17:31159009-31159009 31
35 COSM93509879 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.2409+1G>A p.? 17:31227607-31227607 31
36 COSM120509488 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.205-1G>C p.? 17:31159009-31159009 31
37 COSM93507010 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7237C>T p.Q2413* 17:31349230-31349230 31
38 COSM93662933 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7582C>T p.Q2528* 17:31352381-31352381 31
39 COSM93654948 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7646C>G p.S2549* 17:31356490-31356490 31
40 COSM93504734 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1721+3A>T p.? 17:31221932-31221932 31
41 COSM93507162 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1466A>G p.Y489C 17:31214524-31214524 31
42 COSM120515658 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.226G>T p.E76* 17:31159031-31159031 31
43 COSM93650764 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7300C>T p.Q2434* 17:31349230-31349230 31
44 COSM93517207 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7519C>T p.Q2507* 17:31352381-31352381 31
45 COSM109960306 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1724A>T p.Y575F 17:31221932-31221932 31
46 COSM93652933 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.205-1G>C p.? 17:31159009-31159009 31
47 COSM93668028 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1722-1G>A p.? 17:31223443-31223443 31
48 COSM93647950 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1721+3A>T p.? 17:31221932-31221932 31
49 COSM93688082 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.6855C>A p.Y2285* 17:31338739-31338739 31
50 COSM109961525 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.205-1G>C p.? 17:31159009-31159009 31

Expression for Adrenal Carcinoma

Search GEO for disease gene expression data for Adrenal Carcinoma.

Pathways for Adrenal Carcinoma

Pathways related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.45 POMC CYP21A2 CYP17A1 CYP11B2 CYP11B1
2
Show member pathways
12.4 POMC CYP21A2 CYP17A1 CYP11B2 CYP11B1
3
Show member pathways
12.19 POMC HSD3B2 CYP21A2 CYP17A1 CYP11B2 CYP11B1
4 11.52 POMC HSD3B2 CYP21A2 CYP11B1
5
Show member pathways
11.23 HSD3B2 CYP17A1 CYP11B1
6
Show member pathways
11.09 POMC HSD3B2 CYP21A2 CYP17A1 CYP11B2 CYP11B1
7 10.79 CYP21A2 CYP17A1 CYP11B2 CYP11B1
8 10.5 HSD3B2 CYP17A1
9
Show member pathways
10.34 HSD3B2 CYP11B2

GO Terms for Adrenal Carcinoma

Biological processes related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 regulation of blood pressure GO:0008217 9.92 CHGA CYP11B1 POMC REN
2 steroid metabolic process GO:0008202 9.88 CYP21A2 CYP17A1 CYP11B2 CYP11B1
3 sterol metabolic process GO:0016125 9.85 CYP21A2 CYP11B2 CYP11B1
4 C21-steroid hormone biosynthetic process GO:0006700 9.8 CYP11B2 CYP11B1
5 cortisol metabolic process GO:0034650 9.78 CYP11B2 CYP11B1
6 cortisol biosynthetic process GO:0034651 9.76 CYP11B2 CYP11B1
7 aldosterone biosynthetic process GO:0032342 9.73 CYP11B2 CYP11B1
8 cellular response to peptide hormone stimulus GO:0071375 9.63 MEN1 CYP11B2 CYP11B1
9 mineralocorticoid biosynthetic process GO:0006705 9.56 CYP21A2 CYP11B2
10 steroid biosynthetic process GO:0006694 9.56 HSD3B2 CYP21A2 CYP17A1 CYP11B2 CYP11B1
11 glucocorticoid biosynthetic process GO:0006704 9.23 CYP21A2 CYP17A1 CYP11B2 CYP11B1

Molecular functions related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 9.97 CYP21A2 CYP17A1 CYP11B2 CYP11B1
2 iron ion binding GO:0005506 9.92 CYP21A2 CYP17A1 CYP11B2 CYP11B1
3 corticosterone 18-monooxygenase activity GO:0047783 9.56 CYP11B2 CYP11B1
4 steroid 11-beta-monooxygenase activity GO:0004507 9.46 CYP11B2 CYP11B1
5 monooxygenase activity GO:0004497 9.26 CYP21A2 CYP17A1 CYP11B2 CYP11B1
6 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 8.92 CYP21A2 CYP17A1 CYP11B2 CYP11B1

Sources for Adrenal Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....